Template:KDRG: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 26: | Line 26: | ||
#[[Sparsentan]] | #[[Sparsentan]] | ||
#[[BRENZAVVY- bexagliflozin]] | #[[BRENZAVVY- bexagliflozin]] | ||
#[[New GOLD 2024 Recommendation | #[[Chronic obstructive pulmonary disease history and symptoms]] | ||
#[[COPD Patient with suspected Exacerbation(New GOLD 2024 Recommendation)]] | |||
#[[Nirsevimab]] | #[[Nirsevimab]] | ||
#[[Xacduro- sulbactam and durlobactam]] | #[[Xacduro- sulbactam and durlobactam]] | ||
Revision as of 02:33, 13 June 2024
Kosar Doraghi, M.D.
Current Position
Associate Editor-in-Chief, Beth Israel Deaconess Medical Center by Harvard Medical School, Boston, Massachusetts, USA, WikiDoc Scholar
Pages Authored/Co-authored/Collaborated
- NEXOBRID
- RELYVRIO
- Deucravacitinib
- Ublituximab-xiiy
- futibatinib
- Tapinarof
- Spevigo- spesolimab-sbz
- Vericiguat
- Dasiglucagon
- Ponesimod
- Lasmiditan
- Nirogacestat
- Nedosiran
- Ryzneuta
- Endocarditis overview
- Sparsentan
- BRENZAVVY- bexagliflozin
- Chronic obstructive pulmonary disease history and symptoms
- COPD Patient with suspected Exacerbation(New GOLD 2024 Recommendation)
- Nirsevimab
- Xacduro- sulbactam and durlobactam
- EXXUA
- Somatrogon-ghla
- Chronic renal failure overview
- Aprocitentan
- WINREVAIR
- Xolremdi